Find Local Endocrine Clinical Studies with Clinical Trials GPS

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Wheaton Franciscan Cancer Care - All Saints

from

Racine, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Duke Raleigh Hospital

from

Raleigh, NC

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Northwest Hospital Center

from

Randallstown, MD

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser Permanente-Redwood City

from

Redwood City, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Radiation Oncology Associates

from

Reno, NV

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Valley Medical Center

from

Renton, WA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Mary's Hospital

from

Rhinelander, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Bon Secours Saint Mary's Hospital

from

Richmond, VA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Virginia Cancer Institute

from

Richmond, VA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser Permanente Riverside

from

Riverside, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

North Memorial Medical Health Center

from

Robbinsdale, MN

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Harbin Clinic Medical Oncology and Clinical Research

from

Rome, GA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Sutter Roseville Medical Center

from

Roseville, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Cancer Care Associates PC

from

Royal Oak, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Helena Hospital

from

Saint Helena, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Norris Cotton Cancer Center-North

from

Saint Johnsbury, VT

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Mercy Hospital Saint Louis

from

Saint Louis, MO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Carolina Oncology Associates PA

from

Salisbury, NC

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Utah Cancer Specialists-Salt Lake City

from

Salt Lake City, UT

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

LDS Hospital

from

Salt Lake City, UT

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser Permanente-San Diego Zion

from

San Diego, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser Permanente San Leandro

from

San Leandro, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser Permanente San Rafael

from

San Rafael, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kootenai Cancer Clinic

from

Sandpoint, ID

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser Permanente-Santa Rosa

from

Santa Rosa, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Memorial Health University Medical Center

from

Savannah, GA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Maine Center for Cancer Medicine-Scarborough

from

Scarborough, ME

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Swedish Medical Center-Ballard Campus

from

Seattle, WA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Minor and James Medical, PLLC

from

Seattle, WA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Swedish Medical Center-First Hill

from

Seattle, WA

Louisiana State University Health Sciences Center-Shreveport

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Shreveport, LA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Dayton Physicians LLC-Wilson

from

Sidney, OH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Siouxland Regional Cancer Center

from

Sioux City, IA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser Permanente Cancer Treatment Center

from

South San Francisco, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Greenville Health System Cancer Institute-Spartanburg

from

Spartanburg, SC

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Spartanburg Medical Center

from

Spartanburg, SC

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Evergreen Hematology and Oncology, PS

from

Spokane, WA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Rockwood Clinic Cancer Treatment Center-Valley

from

Spokane Valley, WA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Mercy Medical Center

from

Springfield, MA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Cox Medical Center South

from

Springfield, MO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Mercy Hospital Springfield

from

Springfield, MO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Geisinger Medical Group

from

State College, PA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Mitchell Folbe MD PC

from

Sterling Heights, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Lakeview Hospital

from

Stillwater, MN

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Stony Brook University Medical Center

from

Stony Brook, NY

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Missouri Baptist Outpatient Center-Sunset Hills

from

Sunset Hills, MO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

MultiCare Tacoma General Hospital

from

Tacoma, WA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Joseph's Hospital/Children's Hospital-Tampa

from

Tampa, FL

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Carle Foundation Hospital

from

Urbana, IL

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

South Georgia Medical Center - Pearlman Cancer Ctr

from

Valdosta, GA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Inspira Medical Center Vineland

from

Vineland, NJ

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Ridgeview Medical Center

from

Waconia, MN

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

University Hospitals Sharon Health Center

from

Wadsworth, OH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint John Macomb-Oakland Hospital

from

Warren, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

UW Cancer Center at ProHealth Care

from

Waukesha, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Henry Ford West Bloomfield Hospital

from

West Bloomfield, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Methodist West Hospital

from

West Des Moines, IA

Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, University of Pittsburgh

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Univ of Massachusetts Med School

from

Worcester, MA

Obesity Clinical Trial

Impact of Fitbit Plus Weight Management Program on Physical Activity and Metabolic Disease in Obese Adolescents

Status: Enrolling
Updated: 7/23/2015

UH Rainbow Babies and Children's Hospital

from

Cleveland, OH

BIPOLAR DISORDER Clinical Trial

Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar Disorder

Status: Enrolling, Phase III
Updated: 1/23/2018

from

Pittsburgh, PA

Cardiology / Vascular Diseases, Endocrinology Clinical Trial

Identify Genetic Variations That Affect The Ability of Patients To Metabolize Drugs Through Metabolic Pathways

Status: Enrolling
Updated: 8/14/2015

Sevierville Foot and Ankle Clinic

from

Sevierville, TN

Familial Partial Lipodystrophy Clinical Trial

Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma

Status: Enrolling, Phase II
Updated: 12/31/1969

Emory University

from

Atlanta, GA

Hypophosphatasia Clinical Trial

Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)

Status: Enrolling, Phase
Updated: 12/31/1969

Colorado Center for Bone Research

from

Lakewood, CO

Hypothyroidism Clinical Trial

Desiccated Thyroid Extract Versus Synthetic T3/T4 Combination (ThyrolarTM) Versus L-T4 Alone in the Therapy of Primary Hypothyroidism With Special Attention to the Gene Polymorphism

Status: Enrolling
Updated: 5/5/2015

Walter Reed National Military Medical Center

from

Besthesda, MD

Endocrinology, Reproductive Clinical Trial

Preservation of Ovarian Tissue and Chemo-Radiotherapy

Status: Enrolling
Updated: 12/31/1969

Methodist/LeBonheur Hospital

from

Germantown, TN

Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients

Status: Enrolling, Phase II
Updated: 12/31/1969

UT Southwestern Medical Center 5323 Harry Hines Blvd

from

Dallas, TX

Lymphangioleiomyomatosis Clinical Trial

Safety and Durability of Sirolimus for Treatment of LAM

Status: Enrolling, Phase
Updated: 4/10/2018

Vanderbilt University Medical Center

from

Nashville, TN

Lymphangioleiomyomatosis Clinical Trial

Safety and Durability of Sirolimus for Treatment of LAM

Status: Enrolling, Phase
Updated: 4/10/2018

National Institutes of Health

from

Bethesda, MD

Lymphangioleiomyomatosis Clinical Trial

Safety and Durability of Sirolimus for Treatment of LAM

Status: Enrolling, Phase
Updated: 4/10/2018

The University of Pennsylvania Medical Center

from

Philadelphia, PA

Cardiology / Vascular Diseases, Endocrinology, Hematology, Nephrology / Urology Clinical Trial

18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia

Status: Enrolling, Phase
Updated: 12/31/1969

Children's Hospital of Philadelphia

from

Philadelphia, PA

Preventing Sickle Cell Kidney Disease

Status: Enrolling, Phase II
Updated: 4/30/2018

University of Alabama at Birmingham

from

Birmingham, AL

Sarcoidosis Clinical Trial

Riociguat for Sarcoidosis Associated Pulmonary Hypertension

Status: Enrolling, Phase IV
Updated: 12/4/2015

University of Cincinnati

from

Cincinnati, OH

Endocrinology, Nephrology / Urology Clinical Trial

Pharmacokinetics of Apixaban in Nephrotic Syndrome

Status: Enrolling, Phase I
Updated: 12/31/1969

University of North Carolina at Chapel Hill

from

Chapel Hill, NC

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Status: Enrolling, Phase II
Updated: 12/31/1969

Duke Univ Med Ctr

from

Durham, NC

Idiopathic Focal Segmental Glomerulosclerosis Clinical Trial

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Status: Enrolling, Phase II
Updated: 12/31/1969

Hoag Memorial Hospital

from

Newport Beach, CA

Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS

Status: Enrolling, Phase IV
Updated: 12/31/1969

Ochsner Clinic Foundation-Baton Rouge

from

Baton Rouge, LA

Idiopathic Focal Segmental Glomerulosclerosis Clinical Trial

Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS

Status: Enrolling, Phase IV
Updated: 12/31/1969

California Institute of Renal Research

from

Chula Vista, CA

Idiopathic Focal Segmental Glomerulosclerosis Clinical Trial

Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS

Status: Enrolling, Phase IV
Updated: 12/31/1969

University of Cincinnati Physicians Company, LLC

from

Cincinnati, OH

Idiopathic Focal Segmental Glomerulosclerosis Clinical Trial

Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS

Status: Enrolling, Phase IV
Updated: 12/31/1969

Eastern Nephrology Associates

from

Greenville, NC

Idiopathic Focal Segmental Glomerulosclerosis Clinical Trial

Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS

Status: Enrolling, Phase IV
Updated: 12/31/1969

University of Louisville Research Foundation, Inc.

from

Louisville, KY

Idiopathic Focal Segmental Glomerulosclerosis Clinical Trial

Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS

Status: Enrolling, Phase IV
Updated: 12/31/1969

Icahn School of Medicine at Mt Sinai

from

New York, NY

Idiopathic Focal Segmental Glomerulosclerosis Clinical Trial

Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS

Status: Enrolling, Phase IV
Updated: 12/31/1969

Columbia University Medical Center

from

New York, NY

Cardiology / Vascular Diseases, Endocrinology, Gastroenterology Clinical Trial

Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy

Status: Enrolling, Phase III
Updated: 12/31/1969

National Institutes of Health Clinical Center, 9000 Rockville Pike

from

Bethesda, MD

Prediabetes Clinical Trial

Mitochondrial-related Platelet Transcript Expression Levels in Pre-diabetic Subjects Randomized to Metformin or Placebo

Status: Enrolling, Phase I
Updated: 8/15/2016

University of Utah

from

Salt Lake City, UT

Acromegaly Clinical Trial

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

Status: Enrolling, Phase III
Updated: 12/31/1969

University of Alabama at Birmingham

from

Birmingham, AL

Acromegaly Clinical Trial

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

Status: Enrolling, Phase III
Updated: 12/31/1969

Palm Research Center

from

Las Vegas, NV

Acromegaly Clinical Trial

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

Status: Enrolling, Phase III
Updated: 12/31/1969

Keck Medical Center of University of Southern California

from

Los Angeles, CA

Anaplastic Thyroid Cancer Clinical Trial

Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer

Status: Enrolling, Phase II
Updated: 12/31/1969

U.T. Southwestern Medical Center

from

Dallas, TX

Cystic Fibrosis Clinical Trial

Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance

Status: Enrolling, Phase
Updated: 12/31/1969

Children's Hospital of Philadelphia

from

Philadelphia, PA

Glycogen Storage Disease Clinical Trial

Glycosade v UCCS in the Dietary Management of Hepatic GSD

Status: Enrolling
Updated: 12/31/1969

Connecticut Children's Medical Center

from

Hartford, CT

Insulin Resistance Clinical Trial

Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)

Status: Enrolling, Phase
Updated: 12/31/1969

Pennington Biomedical Research Center

from

Baton Rouge, LA

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Nationwide Children's Hospital

from

Columbus, OH

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

St. Jude Children's Research Hospital

from

Memphis, TN

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Children's Hospital of Philadelphia

from

Philadelphia, PA

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser Permanente - Anaheim

from

Anaheim, CA

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Dana-Farber Cancer Institute

from

Boston, MA

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

UNC Lineberger Comprehensive Cancer Center

from

Chapel Hill, NC

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

Medical University of South Carolina

from

Charleston, SC

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Status: Enrolling, Phase II
Updated: 12/31/1969

UT Southwestern/Simmons Cancer Center-Dallas

from

Dallas, TX